-
公开(公告)号：US11059778B2
公开(公告)日：2021-07-13
申请号：US16872138
申请日：2020-05-11
Inventor： Xiang-Qun Xie , Abdulrahman Almehizia , Peng Yang
IPC: C07C311/29 , C07D405/12 , C07D409/12 , C07D333/34 , C07D333/38 , C07C311/13 , C07C311/18 , C07D401/12 , C07D241/44 , A61P19/10 , A61P35/00 , C07D213/42 , C07D317/58
Abstract: Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
-
公开(公告)号：US20180141902A1
公开(公告)日：2018-05-24
申请号：US15580539
申请日：2016-06-17
Inventor： Xiang-Qun Xie , Abdufrahman Almehizia , Peng Yang
IPC: C07C311/29 , A61P35/00 , A61P19/10 , C07C311/18 , C07D333/38 , C07D241/44 , C07C311/13 , C07D333/34 , C07D409/12 , C07D401/12 , C07D213/42 , C07D317/58 , C07D405/12
CPC classification number: C07C311/29 , A61P19/10 , A61P35/00 , C07C311/13 , C07C311/18 , C07D213/42 , C07D241/44 , C07D317/58 , C07D333/34 , C07D333/38 , C07D401/12 , C07D405/12 , C07D409/12
Abstract: Disclosed herein are novel cannabinoid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
-
Patent Agency Ranking
公开(公告)号：US20200270205A1
公开(公告)日：2020-08-27
申请号：US16872138
申请日：2020-05-11
Inventor： Xiang-Qun XIE , Abdulrahman Almehizia , Peng Yang
IPC: C07C311/29 , C07D405/12 , C07D409/12 , C07D333/34 , C07D333/38 , C07C311/13 , C07C311/18 , C07D401/12 , C07D241/44 , A61P19/10 , A61P35/00 , C07D213/42 , C07D317/58
Abstract: Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
-
4.发明授权Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases 有权大麻素受体2（CB2）反向激动剂和多发性骨髓瘤和骨质疏松症骨病的治疗潜力公开(公告)号：US08772541B2
公开(公告)日：2014-07-08
申请号：US13715603
申请日：2012-12-14
Inventor： Xiang-qun Xie , Peng Yang , Rentian Feng
IPC: A01N41/06 , A01N37/18 , A01N33/02 , A61K31/18 , A61K31/165 , A61K31/135 , C07C303/00 , C07C307/00 , C07C309/00 , C07C311/00 , C07C239/00 , C07C321/00
CPC classification number: C07C233/40 , C07C69/78 , C07C233/11 , C07C233/13 , C07C233/22 , C07C233/36 , C07C233/63 , C07C233/78 , C07C311/05 , C07C311/18 , C07C311/20 , C07C311/29 , C07C311/48 , C07C2601/14 , C07C2603/74 , C07D203/08 , C07D211/06 , C07D213/56 , C07D235/12 , C07D295/135
Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
Abstract translation: 大麻素受体-2反向拮抗剂包括由式IV表示的化合物或其药学上可接受的盐：其中：R 1和R 2独立地为H，烷基或烯基; R3是烷基，烯基，芳基，芳烷基，芳烯基，杂环基，杂环基烷基，杂芳基，杂芳基烷基; R4和R5独立地是键，亚烷基或烯基; 每个R 6和R 7独立地选自OH，F，Cl，Br，I，（C 1 -C 6）烷基，烷氧基，氨基，COOH，CONH 2，SO 3 H，PO 3 H 2，CN，SH，NO 2和CF 3; 且p和q独立地为0,1,2,3,4或5.这些化合物可用于治疗骨质疏松症或多发性骨髓瘤。
-
5.发明申请NOVEL CANNABINOID RECEPTOR 2 (CB2) INVERSE AGONISTS AND THERAPEUTIC POTENTIAL FOR MULTIPLE MYELOMA AND OSTEOPOROSIS BONE DISEASES 有权新的卡那霉素受体2（CB2）多发性骨髓瘤和骨质疏松症的反转激素和治疗潜力公开(公告)号：US20130172388A1
公开(公告)日：2013-07-04
申请号：US13715603
申请日：2012-12-14
Inventor： Xiang-qun XIE , Rentian Feng , Peng Yang
IPC: C07C311/48 , C07D203/08 , C07C69/78 , C07C311/05 , C07D211/06 , C07C233/36 , C07C311/20 , C07C311/29 , C07D235/12 , C07C233/40
CPC classification number: C07C233/40 , C07C69/78 , C07C233/11 , C07C233/13 , C07C233/22 , C07C233/36 , C07C233/63 , C07C233/78 , C07C311/05 , C07C311/18 , C07C311/20 , C07C311/29 , C07C311/48 , C07C2601/14 , C07C2603/74 , C07D203/08 , C07D211/06 , C07D213/56 , C07D235/12 , C07D295/135
Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
Abstract translation: 大麻素受体-2反向拮抗剂包括由式IV表示的化合物或其药学上可接受的盐：其中：R 1和R 2独立地为H，烷基或烯基; R3是烷基，烯基，芳基，芳烷基，芳烯基，杂环基，杂环基烷基，杂芳基，杂芳基烷基; R4和R5独立地是键，亚烷基或烯基; 每个R 6和R 7独立地选自OH，F，Cl，Br，I，（C 1 -C 6）烷基，烷氧基，氨基，COOH，CONH 2，SO 3 H，PO 3 H 2，CN，SH，NO 2和CF 3; 且p和q独立地为0,1,2,3,4或5.这些化合物可用于治疗骨质疏松症或多发性骨髓瘤。
-
公开(公告)号：US10696624B2
公开(公告)日：2020-06-30
申请号：US15580539
申请日：2016-06-17
Inventor： Xiang-Qun Xie , Abdulrahman Almehizia , Peng Yang
IPC: C07C311/29 , C07D405/12 , C07D409/12 , C07D333/34 , C07D333/38 , C07C311/13 , C07C311/18 , C07D401/12 , C07D241/44 , A61P19/10 , A61P35/00 , C07D213/42 , C07D317/58
Abstract: Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
-
7.发明授权Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases 有权大麻素受体2（CB2）反向激动剂和多发性骨髓瘤和骨质疏松症骨病的治疗潜力公开(公告)号：US09376380B2
公开(公告)日：2016-06-28
申请号：US14305941
申请日：2014-06-16
Inventor： Xiang-qun Xie , Peng Yang , Rentian Feng
IPC: C07C233/40 , C07C311/20 , C07C311/05 , C07D211/06 , C07C311/48 , C07D235/12 , C07D203/08 , C07C69/78 , C07C233/36 , C07C311/29 , C07D295/135 , C07D213/56 , C07C311/18 , C07C233/11 , C07C233/13 , C07C233/22 , C07C233/63 , C07C233/78
CPC classification number: C07C233/40 , C07C69/78 , C07C233/11 , C07C233/13 , C07C233/22 , C07C233/36 , C07C233/63 , C07C233/78 , C07C311/05 , C07C311/18 , C07C311/20 , C07C311/29 , C07C311/48 , C07C2601/14 , C07C2603/74 , C07D203/08 , C07D211/06 , C07D213/56 , C07D235/12 , C07D295/135
Abstract: Cannabionid receptor-2 inverse antagonists include compounds represented by Formula IV, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 are independently H, alkyl, or alkenyl; R3 is alkyl, alkenyl, aryl, aralkyl, aralkenyl, heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl; R4 and R5 are independently a bond, alkylenyl, or alkenylenyl; each R6 and R7 is independently selected from the group consisting of OH, F, Cl, Br, I, (C1-C6)alkyl, alkoxy, amino, COOH, CONH2, SO3H, PO3H2, CN, SH, NO2 and CF3; and p and q are independently 0, 1, 2, 3, 4, or 5. Such compounds may be used to treat osteoporosis or multiple myeloma.
Abstract translation: 大麻素受体-2反向拮抗剂包括由式IV表示的化合物或其药学上可接受的盐：其中：R 1和R 2独立地为H，烷基或烯基; R3是烷基，烯基，芳基，芳烷基，芳烯基，杂环基，杂环基烷基，杂芳基，杂芳基烷基; R4和R5独立地是键，亚烷基或烯基; （C 1 -C 6）烷基，烷氧基，氨基，COOH，CONH 2，SO 3 H，PO 3 H 2，CN，SH，NO 2和CF 3; 且p和q独立地为0,1,2,3,4或5.这些化合物可用于治疗骨质疏松症或多发性骨髓瘤。
-
-
-
-
-
-
Search Results
7
records
(took 0.029 seconds)
